(Circulation. 2001;103:e9038.)
© 2001 American Heart Association, Inc.
New Food and Drug Administration Office and Director Named to Oversee Human Research Studies
A new office created by officials at the US Food and Drug Administration (FDA) will concentrate the agencys activities in the area of human research subject protection under the direction of David Lepay, MD, PhD, who was appointed April 23, 2001, to head the Office for Human Research Trials.
Dr Lepay, who was previously a senior advisor of clinical science at the FDA, will coordinate the monitoring program for human clinical trials and oversee its good clinical practice policy. His office will also participate in such activities on an international level and coordinate with the Office of Human Research Protections in the US Department of Health and Human Services.
The move is only the latest in a series at the federal level to tighten the monitoring of medical research involving human beings.
Link Found Between Nurse Staffing and Patient Outcomes
The number of nurses in a hospital and the mix of their capabilities made a difference in the quality of care that patients receive, according to a study released April 20, 2001, by the US Department of Health and Human Services (HHS) Health Research and Services Administration (HRSA).
The study was based on data from records of 5
million hospital discharges from 799 hospitals in 11 states in 1997.
The analysis of the data showed that there was a "strong and
consistent relationship" between nurse staffing and 5
outcomes in patients: urinary tract infection, pneumonia, shock, upper
gastrointestinal bleeding, and length of stay. In the study, more
registered nurses in clinical positions at the hospital was associated
with
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |